Camurus AB: 2 directors

Two Directors at Camurus AB sold 120,000 shares at between 696.077SEK and 706.103SEK. The significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...

ABGSC Shipping Daily 24 July

Camurus: Brixadi bounced back; optionality provided in the incretin sp...

Camurus' Q2 earnings main takeaway was Brixadi rebounding sharply (+32% QoQ at CER), signalling that earlier US market headwinds - insurance renewals, CJS funding delays and destocking - have largely resolved. Prescription data (TRx) for Q2 was 2.1x YoY, supporting our estimate of c. 51k patients o

ABGSC Shipping Daily 17 July

Camurus Q2: Brixadi renewed growth, Buvidal slowed

Camurus reported its Q2 2025 results, highlighted by renewed growth for Brixadi in the US at CER (still impacted by FX headwinds), a slowing of Buvidal and a beat on profitability. Total revenues came in at SEK676m (c. +6.8% vs css) and PBT at SEK307m (+14,6% vs css), impacted by the USD12m upfront

Higher rates lift Q3 EBITDA by 31%

Q2 trading update: Volumes and prices a tad below cons

Camurus: Oczyesa gains EU approval for Acromegaly

Oclaiz/Oczyesa (Octreotide LAI, somatostatin analogue SSA) gained EU approval for Acromegaly - largely expected following the positive CHMP opinion in April'25. While the commercial potential in EU is rather limited for the indication (we estimate USD170m in total peak sales, with the US accounting

Seafood - Norwegian biomass update

Seafood - Norwegian biomass update

Seafood - Fat Trout Weekly

Seafood - Fat Trout Weekly

Camurus: CAM2029 Ph2/3 in PLD met primary endpoint, follow up Ph3 TBD

Camurus reported topline data from its phase 2/3 POSITANO study (n=71) evaluating CAM2029 in PLD which met the primary endpoint showing stat. sig. relative reduction of the liver volume (htTLV) from baseline to week 53 of 4.3% (p=0.044) vs pbo, with corresponding relative reduction in total liver c

Seafood - Fat Trout Weekly

Seafood - Fat Trout Weekly

Camurus: Signs USD870m deal with Lilly for LAI incretins

Camurus signed a USD870m deal with Eli Lilly, licensing its FluidCrystal technology for up to four long-acting injectable (LAI) incretin candidates. The upfront, development and regulatory milestones of USD290, combined with USD580m in sales milestones and tiered mid-single digit royalties, further

Seafood - Fat Trout Weekly

Seafood - Fat Trout Weekly

Seafood - Fat Trout Weekly

Seafood - Fat Trout Weekly

Seafood - Norwegian biomass update

Seafood - Norwegian biomass update

Rates above USD 60k/day, but 0.7x P/NAV

Q1 above, Q2 below, net neutral

US terminal expansions are on track

Camurus Q1: Beat on profitability, Buvidal/Brixadi momentum preserved

Camurus reported its Q1'25 results, with topline revenues of SEK558m (c. -6% vs css, primarily due to FX), and a beat on profitability with PBT coming in at SEK254m (c. +20% vs css). Buvidal maintained its growth momentum in Q1 with 3,000 new patients on treatment (vs. 4,000 in Q4, but consistent w